Montelukast As An Adjunct To Treatment of Chronic Rhinosinusitis With Polyposis: A Prospective Randomized Controlled Trial.
Loading...
Date
2015-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In a prospective, randomized controlled trial, forty consecutive adult patients with bilateral nasal polyps
were randomized into two groups. Twenty subjects in Group A were treated with oral prednisolone for 14
days and budenoside nasal spray for 8 weeks while the twenty subjects in Group B received a similar
treatment with additional oral montelukast for 8 weeks. Subjects completed a modified nasal ICSD symptom
score at the start of treatment and at 8 and 12 weeks after beginning the treatment. Symptom scores
improved in both the groups after treatment. Subjects in Group B reported a statistically significant
improvement in sense of smell (p = 0.0002), sneezing (p = 0.008) and overall score (p = 0.0006) at 8 weeks
than controls. Four weeks after the completion of treatment, a statistically significant improvement was
seen in the sense of smell (p = 0.0006), headache (p = 0.03) and overall score (p = 0.003) in patients in
Group B when compared to Group A. Montelukast therapy may have clinical benefit as an adjunct to oral
and inhaled steroid in chronic nasal polyposis.
Description
Keywords
Montelukast, Chronic Rhinosinusitis, Polyposis, Steroid
Citation
Suri Anil, Gupta Rohan, Gupta Nitika, Kotwal Sunil. Montelukast As An Adjunct To Treatment of Chronic Rhinosinusitis With Polyposis: A Prospective Randomized Controlled Trial. JK Science Journal of Medical Education and Research. 2015 Apr-June; 17(2): 92-95.